Navigation Links
Encision Enters Into Sales Representation Agreement With Caldera Medical
Date:3/25/2009

BOULDER, Colo., March 25 /PRNewswire-FirstCall/ -- Encision Inc. ("Encision") (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, has entered into an agreement with Caldera Medical, Inc. ("Caldera") to represent Caldera's line of products. Caldera's products include the Desara(R) Sling System for treating stress urinary incontinence which is estimated to affect 15 million women in the U.S. Encision will use its sales employees to supplement Caldera's sales team in introducing Caldera's products to physicians and hospitals.

"We are pleased to expand our product offerings to a key group of our target customers. Caldera's products are consistent with our desire to offer 'best in class' products to the surgical market," said Jack Serino, President and CEO of Encision.

"Through Encision's experienced sales representatives, we will expand coverage throughout the U.S. market and strengthen our presence in the marketplace. This is especially important as we continue to broaden our product portfolio with innovative new technologies," said Bryon L. Merade, CEO of Caldera.

About Encision:

Encision designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM(R) Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery. For more information, visit Encision's web site at www.encision.com.

About Caldera:

Caldera is dedicated to bringing innovative medical devices to the marketplace. Caldera focuses exclusively on differentiated, high-impact products across the gynecology, urology and urogynecology specialties. Caldera is a privately held company located in Agoura Hills, California. For more information, visit Caldera's web site at www.calderamedical.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.

    CONTACT:  Marcia McHaffie, Encision Inc., 303-444-2600,
              mmchaffie@encision.com


'/>"/>
SOURCE Encision Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
2. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
3. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
4. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
5. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
6. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
7. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
8. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
9. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
10. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
11. Sangui Partnership Enters a New Phase:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , ... February 21, 2017 , ... ... cell therapy manufacturing facility at its headquarters laboratory in Poway, California. Based ... the experience of both in-house personnel and consultants, VetStem constructed and validated a ...
(Date:2/21/2017)... and VANCOUVER, British Columbia , ... OGXI ) today announced that apatorsen results from two randomized ... of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium, held February ... . Clinical data from trials in bladder and prostate ... administered in combination with standard-of-care treatments. ...
(Date:2/21/2017)... 2017   Logicalis Healthcare Solutions , the healthcare-focused ... managed services provider ( www.us.logicalis.com ), today announced a ... The new service will help hospital CIOs make the ... physicians, nurses and other clinicians immediate access to a ... will allow hospital IT staff to focus on broader ...
(Date:2/21/2017)... SAN FRANCISCO , Feb. 21, 2017   ... growing genetic information companies, today announced that members of ... and Company 37th Annual Health Care Conference on Monday, ... 1:00 p.m. Pacific in Boston, Massachusetts ... the presentation may be accessed by visiting the investors ...
Breaking Biology Technology:
(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special ... Kephart of Identity Strategy Partners, LLP, today releases ... "Executive Order: Protecting the Nation From Foreign Terrorist Entry ... "As President Trump,s ,Travel Ban, Executive Order gains more ... the travel ban, it is important that our national ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):